FDA inspection
Wuhan Humanwell Likang Pharmaceutical Co., Ltd.: FDA inspection ending Mar 7, 2025
FDA inspection 1266967 · Voluntary Action Indicated (VAI) · Wuhan
Key facts
| Inspection ID | 1266967 |
|---|---|
| Firm | Wuhan Humanwell Likang Pharmaceutical Co., Ltd. |
| FEI number | 3014919801 |
| Address | Donghu New, 98 Shendun 2nd Road; Technology Development Zone |
| City | Wuhan |
| Fiscal year | 2025 |
| Inspection end date | Mar 7, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data